Decision-making using fMRI in clinical drug development: Revisiting NK-1 receptor antagonists for pain

Drug Discovery Today

Volumn 17, Issue 17-18, 2012, Pages 964-973

  Borsook, David ^a,b,c   Upadhyay, Jaymin ^a,b   Klimas, Michael ^a,d   Schwarz, Adam J ^a,e   Coimbra, Alexandre ^a,d   Baumgartner, Richard ^a,d   George, Edward ^a,b   Potter, William Z ^a,d   Large, Thomas ^a,f   Bleakman, David ^a,e   Evelhoch, Jeffrey ^a,d   Iyengar, Smriti ^a,e   Becerra, Lino ^a,b,c   Hargreaves, Richard J ^a,d  

^a Imaging Consortium for Drug Development   (United States)

^b MCLEAN HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANALGESIC AGENT; APREPITANT; AV 608; BUPRENORPHINE; CP 999994; DAPITANT; DEXAMETHASONE; EZLOPITANT; FOSAPREPITANT; IBUPROFEN; LANEPITANT; LY 30387087; SUBSTANCE P; TKA 731; UNCLASSIFIED DRUG; VOFOPITANT;

DECISION MAKING; DIABETIC NEUROPATHY; DRUG SAFETY; DRUG TOLERABILITY; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MENINGITIS; MIGRAINE; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN; POSITRON EMISSION TOMOGRAPHY; POSTHERPETIC NEURALGIA; REVIEW; TOOTH PAIN; VISCERAL PAIN; VOMITING;

ANIMALS; DECISION MAKING; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING; PAIN; RECEPTORS, NEUROKININ-1;

EID: 84865503397     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.05.004     Document Type: Review

References (86)

1. M.P. Curran, and D.M. Robinson Aprepitant: a review of its use in the prevention of nausea and vomiting Drugs 69 2009 1853 1878
2. R. Hargreaves Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting Ann. N.Y. Acad. Sci. 1222 2011 40 48
3. S. Stander Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy PLoS ONE 5 2010 e10968
4. K. Ranga, and R. Krishnan Clinical experience with substance P receptor (NK1) antagonists in depression J. Clin. Psychiatry 63 Suppl. 11 2002 25 29
5. M. Keller Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biol. Psychiatry 59 2006 216 223 (Pubitemid 43208967)
6. J. Tauscher Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder Eur. Neuropsychopharmacol. 20 2010 80 87
7. R.M. Snider A potent nonpeptide antagonist of the substance P (NK1) receptor Science 251 1991 435 437 (Pubitemid 21916907)
8. A.H. Amin The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog J. Physiol. 126 1954 596 618
9. R. Hargreaves Imaging substance P receptors (NK1) in the living human brain using positron emission tomography J. Clin. Psychiatry 63 Suppl. 11 2002 18 24 (Pubitemid 35435004)
10. R.M. Navari Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting Expert Rev. Anticancer Ther. 4 2004 715 724 (Pubitemid 39359859)
11. S. Harrison, and P. Geppetti Substance p Int. J. Biochem. Cell Biol. 33 2001 555 576 (Pubitemid 32510811)
12. N.M. Rupniak Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils Br. J. Pharmacol. 116 1995 1937 1943
13. M.A. Coudore-Civiale Effect of tachykinin receptor antagonists in experimental neuropathic pain Eur. J. Pharmacol. 361 1998 175 184
14. H. Mansikka Neurokinin-1 receptors are involved in behavioral responses to high-intensity heat stimuli and capsaicin-induced hyperalgesia in mice Anesthesiology 90 1999 1643 1649 (Pubitemid 29254810)
15. M.I. Gonzalez Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain J. Pharmacol. Exp. Ther. 294 2000 444 450 (Pubitemid 30490814)
16. J.A. Trafton Differential contribution of substance P and neurokinin A to spinal cord neurokinin-1 receptor signaling in the rat J. Neurosci. 21 2001 3656 3664 (Pubitemid 32422830)
17. R. Hill NK1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol. Sci. 21 2000 244 246 (Pubitemid 30445249)
18. C.M. Cahill, and T.J. Coderre Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist Pain 95 2002 277 285 (Pubitemid 34142651)
19. W.S. Kingery A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II Pain 104 2003 75 84 (Pubitemid 36835876)
20. G.A. Gaudreau, and V. Plourde Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat Neurosci. Lett. 351 2003 59 62 (Pubitemid 37329588)
21. G.M. Pitcher, and J.L. Henry Nociceptive response to innocuous mechanical stimulation is mediated via myelinated afferents and NK-1 receptor activation in a rat model of neuropathic pain Exp. Neurol. 186 2004 173 197 (Pubitemid 38333192)
22. L. Seguin Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent Pain 61 1995 325 343
23. K.A. Sluka Differential roles of neurokinin 1 and neurokinin 2 receptors in the development and maintenance of heat hyperalgesia induced by acute inflammation Br. J. Pharmacol. 120 1997 1263 1273 (Pubitemid 27149676)
24. B.A. Chizh Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers Br. J. Anaesth. 98 2007 246 254 (Pubitemid 47072006)
25. R.A. Dionne The substance P receptor antagonist CP-99,994 reduces acute postoperative pain Clin. Pharmacol. Ther. 64 1998 562 568 (Pubitemid 28531601)
26. R. Reinhardt Comparison of neurokinin-1 antagonist, L-745,030, to placebo, acetaminophen and ibuprofen in the dental pain model Clin. Pharmacol. Ther. 63 1998 168
27. D.J. Goldstein Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy Clin. Neuropharmacol. 24 2001 16 22 (Pubitemid 32176476)
28. S.H. Sindrup The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial Eur. J. Pain 10 2006 567 571 (Pubitemid 43947641)
29. G. Block The substance P receptor antagonist L-754,030 (MK-0869) is ineffective in the treatment of post-herpetic neuralgia Neurology 50 1998 A225
30. D.J. Goldstein Lanepitant, an NK-1 antagonist, in migraine prevention Cephalalgia 21 2001 102 106 (Pubitemid 32575472)
31. D.J. Goldstein Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study Cephalalgia 17 1997 785 790 (Pubitemid 27505105)
32. L.A. Phebus The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs Life Sci. 60 1997 1553 1561 (Pubitemid 27186418)
33. H.C. Diener RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks Cephalalgia 23 2003 183 185
34. B. Norman A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine Cephalalgia 18 1998 407
35. M. Bergstrom Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant Biol. Psychiatry 55 2004 1007 1012 (Pubitemid 38581916)
36. H.E. Connor Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine Cephalalgia 18 1998 392
37. J. Bueller S1816 effects of NK-1 receptor antagonist AV608 on emotional circuitry and affect in female IBS patients Gastroenterology 134 2008 276
38. D.J. Goldstein Study of the analgesic effect of lanepitant in patients with osteoarthritis pain Clin. Pharmacol. Ther. 67 2000 419 426 (Pubitemid 30246820)
39. B.H. Littman Substance P antagonism in fibromyalgia: a trial with CJ-11974 In 9th World Conference on Pain 1999 IASP Press 67
40. P. Holzer, Handbook of Experimental Pharmacology 2004 Springer
41. L. Pradier Molecular determinants of the species selectivity of neurokinin type 1 receptor antagonists Mol. Pharmacol. 47 1995 314 321
42. A. Nagahisa Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation Br. J. Pharmacol. 107 1992 273 275
43. S. Engberg Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors Biochem. Pharmacol. 73 2007 259 269 (Pubitemid 44855727)
44. J. Yip, and L.A. Chahl Localization of tachykinin receptors and Fos-like immunoreactivity induced by substance P in guinea-pig brain Clin. Exp. Pharmacol. Physiol. 27 2000 943 946
45. E.A. Campbell Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea pig Pain 87 2000 253 263 (Pubitemid 30645874)
46. B. Greenwood-Van Meerveld NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig Pharmacol. Biochem. Behav. 74 2003 1005 1013 (Pubitemid 36351664)
47. T. King Unmasking the tonic-aversive state in neuropathic pain Nat. Neurosci. 12 2009 1364 1366
48. D. Borsook A role for fMRI in optimizing CNS drug development Nat. Rev. Drug Discov. 5 2006 411 424
49. D. Borsook, and L. Becerra Emotional pain without sensory pain - dream on? Neuron 61 2009 153 155
50. D. Borsook, and L. Becerra Using NMR approaches to drive the search for new CNS therapeutics Curr. Opin. Invest. Drugs 11 2010 771 778
51. K. Wartolowska, and I. Tracey Neuroimaging as a tool for pain diagnosis and analgesic development Neurotherapeutics 6 2009 755 760
52. D.F. Wong The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology 34 2009 187 203
53. M.N. Baliki The cortical rhythms of chronic back pain J. Neurosci. 31 2011 13981 13990
54. V. Napadow Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity Arthritis Rheum. 62 2010 2545 2555
55. S. Malinen Aberrant temporal and spatial brain activity during rest in patients with chronic pain Proc. Natl. Acad. Sci. U.S.A. 107 2010 6493 6497
56. I. Tracey Getting the pain you expect: mechanisms of placebo, nocebo and appraisal effects in humans Nat. Med. 16 2010 1277 1283
57. R. Peyron Functional imaging of brain responses to pain. A review and meta-analysis Neurophysiol. Clin. 30 2000 263 288
58. A.V. Apkarian Human brain mechanisms of pain perception and regulation in health and disease Eur. J. Pain 9 2005 463 484 (Pubitemid 40836040)
59. S.C. Lidstone, and A.J. Stoessl Understanding the placebo effect: contributions from neuroimaging Mol. Imaging Biol. 9 2007 176 185
60. F. Eippert Activation of the opioidergic descending pain control system underlies placebo analgesia Neuron 63 2009 533 543
61. P. Petrovic Placebo and opioid analgesia: imaging a shared neuronal network Science 295 2002 1737 1740 (Pubitemid 34202913)
62. R.G. Wise Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain Neuropsychopharmacology 29 2004 626 635 (Pubitemid 38365941)
63. L. Becerra Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers Anesth. Analg. 103 2006 208 216 (Pubitemid 44036061)
64. M. Leppa Acute opioid effects on human brain as revealed by functional magnetic resonance imaging Neuroimage 31 2006 661 669 (Pubitemid 43776689)
65. Upadhyay, J. et al. Imaging drugs with and without clinical analgesic Q12 efficacy. Neuropsychopharmacology 36, 2659-2673
66. J. Upadhyay Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine Neuroimage 59 2012 3762 3773
67. G.D. Iannetti Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans Proc. Natl. Acad. Sci. U.S.A. 102 2005 18195 18200 (Pubitemid 41798524)
68. M. Lopez-Sola Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder Neuropsychopharmacology 35 2010 2305 2317
69. A. Hess Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system Proc. Natl. Acad. Sci. U.S.A. 108 2011 3731 3736
70. M.S. Judenhofer Simultaneous PET-MRI: a new approach for functional and morphological imaging Nat. Med. 14 2008 459 465 (Pubitemid 351499385)
71. F.D. Tattersall Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets Neuropharmacology 35 1996 1121 1129 (Pubitemid 27008187)
72. S.E. Huskey Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets Drug Metab. Dispos. 31 2003 785 791
73. D. Borsook CNS response to a thermal stressor in human volunteers and rats may predict the clinical utility of analgesics Drug Dev. Res. 68 2007 23 41 (Pubitemid 46878003)
74. P.Y. Geha The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions Neuron 60 2008 570 581
75. F. Cauda Altered resting state in diabetic neuropathic pain PLoS ONE 4 2009 e4542
76. C.P. Bailey Neurokinin-1 receptors in the rat nucleus tractus solitarius: pre- and postsynaptic modulation of glutamate and GABA release Neuroscience 127 2004 467 479 (Pubitemid 38950661)
77. N.A. Darmani Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists Brain Res. 1214 2008 58 72
78. A.P. Ray Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting Behav. Neurosci. 123 2009 701 706
79. P.W. Mantyh Neurobiology of substance P and the NK1 receptor J. Clin. Psychiatry 63 Suppl. 11 2002 6 10
80. C.A. Gadd Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse J. Neurosci. 23 2003 8271 8280 (Pubitemid 37129644)
81. J. Halasz The effect of neurokinin1 receptor blockade on territorial aggression and in a model of violent aggression Biol. Psychiatry 63 2008 271 278
82. A. Holmes Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends Pharmacol. Sci. 24 2003 580 588 (Pubitemid 37357142)
83. V. Madaan, and D.R. Wilson Neuropeptides: relevance in treatment of depression and anxiety disorders Drug News Perspect. 22 2009 319 324
84. M.S. Kramer Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression Neuropsychopharmacology 29 2004 385 392 (Pubitemid 38180456)
85. D. Borsook Reward-aversion circuitry in analgesia and pain: implications for psychiatric disorders Eur. J. Pain 11 2007 7 20 (Pubitemid 44740511)
86. J.A. Dimasi Risks in new drug development: approval success rates for investigational drugs Clin. Pharmacol. Ther. 69 2001 297 307